Ret Proto-Oncogene Antikörper (AA 702-848)

Produktnummer ABIN6938320

Produktdetails anti-Ret Proto-Oncogene Antikörper

Target: Ret Proto-Oncogene (RET)

Bindungsspezifität: AA 702-848

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Spezifität: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney.Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.

Kreuzreaktivität (Details): Human.

Aufreinigung: 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.

Immunogen: Recombinant fragment (around aa 702-848) of human RET protein (exact sequence is proprietary)

Klon: RET-2795

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise:

Known_Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

Positive_Control: Breast, Prostate or Colon Carcinoma.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: Prepared in 10 mM PBS, WITHOUT BSA and Azide.

Konservierungsmittel: Azide free

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.

Haltbarkeit: 24 months

Details zu Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: RET (RET Produkte)

Synonyme: c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper

Hintergrund: Cadherin family member 12 (CDHF12), Cadherin related family member 16 (CDHR16), ELKS, HSCR1, Hydroxyaryl protein kinase, MEN2A, MEN2B, MTC1, Multiple endocrine neoplasia and medullary thyroid carcinoma 1, Oncogene RET, Proto-oncogene c-Ret, Proto-oncogene tyrosine-protein kinase receptor ret, PTC, RET, RET ELE1, RET51, RET9,RET Proto-oncogene
Cellular localisation: Cytoplasmic, Cell Surface and Nuclear

Molekulargewicht: 150kDa (precursor), 170kDa (Mature)

Gen-ID: 5979, 350321

UniProt: P07949

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation